Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Evaxion Biotech Business Update Full Year 2024 Conference Call and Webcast.
Evaxion Biotech A/S (EVAX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 6,018.48 | $127,201 | -69% | 0% |
| 2. | Millennium Management Israel Englander | 901.64 | $18,772 | 0% | |
| 3. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% |
Institutional Investors' Holdings
News See All
Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Evaxion Biotech Business Update Conference call. [Operator Instructions] Please be advised, that today's conference is being recorded.
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript
Christian Kanstrup: Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the back of our Full Year 2023 Results. I'm Christian Kanstrup. I'm the CEO of Evaxion.
Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Evaxion Biotech Q2 Results Call. At this time, all participants are in a listen-only mode.
10 Best Immunotherapy Stocks To Buy Now
The global immunotherapy market is rapidly evolving as technological, regulatory, and economic trends combine to alter the growth and risk dynamics within the industry.
Is Evaxion Biotech A/S (EVAX) A Good Stock To Buy?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter.
Billionaire Hedge Funds
